Loading...
Loading...
Rainbow Coral Corp.
RBCC and its joint venture partner,
Therakine, Ltd., are pleased to announce that they have reached a major
new milestone in the development of a revolutionary new drug delivery
technology. This week, the companies reached terms to initiate Phase II
of research and analysis on a new injectable, sustained-release
technology poised to vastly improve patients' use of a crucial drug in
the fight against drug and alcohol dependence.
Naltrexone is a prescription opioid receptor antagonist used primarily
in the management of alcohol and opioid dependence. Phase I of the joint
venture's research established excellent compatibility between the drug
and Therakine's hydrophobic injection matrix as well as a highly
promising release
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in